{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T20:34:39Z","timestamp":1795034079161,"version":"4.10.2"},"reference-count":196,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Aplastic anemia is a rare, life-threatening condition marked by pancytopenia and bone marrow hypocellularity. Despite therapeutic advances, clinical practice remains variable, and uncertainties persist regarding diagnosis and optimal management. To address these gaps, the American Society of Hematology (ASH) developed evidence-based guidelines to provide standardized, patient-centered recommendations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The recommendations are intended to support patients, clinicians, and other health care professionals in their decisions about the management and diagnosis of severe and very severe immune-acquired aplastic anemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>ASH formed a multidisciplinary guideline panel of content experts, methodologists, and a patient representative. An evidence synthesis team supported the guideline development process by conducting systematic evidence reviews. The panel prioritized clinical questions and used the grading of recommendations assessment, development, and evaluation approach, including the evidence-to-decision frameworks, to assess evidence and make recommendations, which were subject to public comment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The panel agreed on 33 recommendations and 4 good practice statements addressing the use of diagnostic tests, treatment strategies and supportive care. Additional recommendations covered the incorporation of eltrombopag into immunosuppressive regimens and the use of antimicrobial prophylaxis for patients at high risk. For most clinical questions, the certainty in the evidence was rated as low or very low, largely due to the reliance on small, nonrandomized studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Recommendations emphasize prioritizing hematopoietic cell transplantation for younger individuals with an available matched sibling or unrelated donor and as a second-line option after failure of immunosuppressive therapy. The panel also recommended adding eltrombopag to immunosuppressive regimens and using antibiotic and antifungal prophylaxis for patients with neutropenia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025019051","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T14:13:30Z","timestamp":1775052810000},"page":"5962-5990","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["American Society of Hematology 2026 guidelines for the diagnosis and management of severe and very severe acquired aplastic anemia"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9047-4538","authenticated-orcid":false,"given":"Phillip","family":"Scheinberg","sequence":"first","affiliation":[{"name":"1Division of Hematology, Hospital A Benefic\u00eancia Portuguesa de S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra A.","family":"O\u2019Neal","sequence":"additional","affiliation":[{"name":"2Newark, DE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9892-5543","authenticated-orcid":false,"given":"Ana Lisa","family":"Basquiera","sequence":"additional","affiliation":[{"name":"3Oncology and Hematology Department, Hospital Privado Universitario de C\u00f3rdoba, Instituto Universitario de Ciencias Biom\u00e9dicas de C\u00f3rdoba, C\u00f3rdoba, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Byrne","sequence":"additional","affiliation":[{"name":"4Hematology Department, Tennessee Oncology, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7966-6029","authenticated-orcid":false,"given":"Rodrigo","family":"Calado","sequence":"additional","affiliation":[{"name":"5Department of Clinical Medicine, University of S\u00e3o Paulo, Ribeir\u00e3o Preto, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3221-8536","authenticated-orcid":false,"given":"Ruchi","family":"Desai","sequence":"additional","affiliation":[{"name":"6Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy E.","family":"DeZern","sequence":"additional","affiliation":[{"name":"7Division of Hematology Malignancies, Johns Hopkins University, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Dufour","sequence":"additional","affiliation":[{"name":"8Clinical and Experimental Haematology Unit, IRCCS Istituto G. Gaslini Research Children\u2019s Hospital, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4648-5926","authenticated-orcid":false,"given":"Emma M.","family":"Groarke","sequence":"additional","affiliation":[{"name":"9Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8554-1687","authenticated-orcid":false,"given":"HyoJeong","family":"Han","sequence":"additional","affiliation":[{"name":"10Division of Hematology, Children\u2019s National Hospital, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3423-1523","authenticated-orcid":false,"given":"Kohei","family":"Hosokawa","sequence":"additional","affiliation":[{"name":"11Department of Hematology, Kanazawa University Hospital, Kanazawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4289-3057","authenticated-orcid":false,"given":"Rina","family":"Kansal","sequence":"additional","affiliation":[{"name":"12Department of Hematology, University at Buffalo, Buffalo, NY"},{"name":"13Versiti Blood Center of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3180-3570","authenticated-orcid":false,"given":"Austin","family":"Kulasekararaj","sequence":"additional","affiliation":[{"name":"14Department of Hematology, King\u2019s College Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherif Beniameen","family":"Mossad","sequence":"additional","affiliation":[{"name":"15Department of Infectious Diseases, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Muus","sequence":"additional","affiliation":[{"name":"16Department of Hematology, St James\u2019s University Hospital, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhumika","family":"Patel","sequence":"additional","affiliation":[{"name":"17Department of Hematology Oncology, Prisma Health, Greenville, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4744-5109","authenticated-orcid":false,"given":"Antonio M.","family":"Risitano","sequence":"additional","affiliation":[{"name":"18Department of Biochemistry and Medical Biotechnologies, Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati, Avellino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1222-6659","authenticated-orcid":false,"given":"Hubert","family":"Schrezenmeier","sequence":"additional","affiliation":[{"name":"19Institute of Transfusion Medicine, Institute of Clinical Transfusion Medicine and Immunogenetics, Ulm University, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3281-2081","authenticated-orcid":false,"given":"Akshay","family":"Sharma","sequence":"additional","affiliation":[{"name":"20Department of Bone Marrow Transplantation & Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4683-9958","authenticated-orcid":false,"given":"Akiko","family":"Shimamura","sequence":"additional","affiliation":[{"name":"21Bone Marrow Failure and Myelodysplastic Syndrome Program, Boston Children's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8371-1040","authenticated-orcid":false,"given":"Kristin A.","family":"Shimano","sequence":"additional","affiliation":[{"name":"22Division of Allergy, Immunology, and Blood and Marrow Transplant, Department of Pediatrics, University of California, San Francisco, Benioff Children\u2019s Hospital, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0303-6055","authenticated-orcid":false,"given":"Fernando","family":"Tortosa","sequence":"additional","affiliation":[{"name":"23Escuela de Medicina, Universidad Nacional de Rio Negro, Rio Negro, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5348-6284","authenticated-orcid":false,"given":"Camila","family":"Avila","sequence":"additional","affiliation":[{"name":"24Facultad de Medicina, Universidad del Desarrollo, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3182-8041","authenticated-orcid":false,"given":"Martin","family":"Ragusa","sequence":"additional","affiliation":[{"name":"25Divisi\u00f3n Cl\u00ednica M\u00e9dica, Hospital Fern\u00e1ndez, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9053-4396","authenticated-orcid":false,"given":"Ariel","family":"Izcovich","sequence":"additional","affiliation":[{"name":"26Divisi\u00f3n Cl\u00ednica M\u00e9dica, Hospital Alem\u00e1n de Buenos Aires, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8406-6880","authenticated-orcid":false,"given":"Ignacio","family":"Neumann","sequence":"additional","affiliation":[{"name":"27Facultad de Medicina, Universidad San Sebasti\u00e1n, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"issue":"3","key":"2026090811322933600_bib1","doi-asserted-by":"crossref","first-page":"E123","DOI":"10.1503\/cmaj.131237","article-title":"Guidelines 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise","volume":"186","author":"Sch\u00fcnemann","year":"2014","journal-title":"CMAJ"},{"key":"2026090811322933600_bib2","volume-title":"Clinical Practice Guidelines We Can Trust","author":"Institute of Medicine Committee on Standards for Developing Trustworthy Clinical Practice Guidelines","year":"2011"},{"key":"2026090811322933600_bib3","author":"Neumann","year":"2024"},{"issue":"3","key":"2026090811322933600_bib4","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/bmjebm-2022-111962","article-title":"Good or best practice statements: proposal for the operationalisation and implementation of GRADE guidance","volume":"28","author":"Dewidar","year":"2023","journal-title":"BMJ Evid Based Med"},{"issue":"1","key":"2026090811322933600_bib5","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1182\/blood.V48.1.63.63","article-title":"Severe aplastic anemia: a prospective study of the effect of early marrow transplantation on acute mortality","volume":"48","author":"Camitta","year":"1976","journal-title":"Blood"},{"issue":"6","key":"2026090811322933600_bib6","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/0145-2126(88)90111-7","article-title":"Aplastic anaemia incidence in parts of the United Kingdom in 1985","volume":"12","author":"Cartwright","year":"1988","journal-title":"Leuk Res"},{"issue":"4","key":"2026090811322933600_bib7","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1182\/blood-2005-01-0161","article-title":"The epidemiology of aplastic anemia in Thailand","volume":"107","author":"Issaragrisil","year":"2006","journal-title":"Blood"},{"issue":"8","key":"2026090811322933600_bib8","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood.V75.8.1646.1646","article-title":"Epidemiology of aplastic anemia in France: a prospective multicentric study. The French Cooperative Group for Epidemiological Study of Aplastic Anemia","volume":"75","author":"Mary","year":"1990","journal-title":"Blood"},{"issue":"4","key":"2026090811322933600_bib9","doi-asserted-by":"crossref","first-page":"518","DOI":"10.3324\/haematol.12020","article-title":"Epidemiology of aplastic anemia: a prospective multicenter study","volume":"93","author":"Montan\u00e9","year":"2008","journal-title":"Haematologica"},{"issue":"1","key":"2026090811322933600_bib10","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1182\/blood.V66.1.115.115","article-title":"Incidence of aplastic anemia in metropolitan Baltimore: a population-based study","volume":"66","author":"Szklo","year":"1985","journal-title":"Blood"},{"issue":"10","key":"2026090811322933600_bib11","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.3324\/haematol.2017.169862","article-title":"Incidence and outcome of acquired aplastic anemia: real-world data from patients diagnosed in Sweden from 2000-2011","volume":"102","author":"Vaht","year":"2017","journal-title":"Haematologica"},{"issue":"1","key":"2026090811322933600_bib12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00277-018-3486-3","article-title":"Incidence and treatment outcome of aplastic anemia in Taiwan-real-world data from single-institute experience and a nationwide population-based database","volume":"98","author":"Li","year":"2019","journal-title":"Ann Hematol"},{"issue":"3","key":"2026090811322933600_bib13","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.bbmt.2018.08.029","article-title":"Allogeneic hematopoietic cell transplantation in patients aged 50 years or older with severe aplastic anemia","volume":"25","author":"Rice","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"4","key":"2026090811322933600_bib14","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.hoc.2018.03.003","article-title":"Recent advances and long-term results of medical treatment of acquired aplastic anemia: are patients cured?","volume":"32","author":"Scheinberg","year":"2018","journal-title":"Hematol Oncol Clin North Am"},{"issue":"4","key":"2026090811322933600_bib15","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/ajh.27611","article-title":"Elderly patients with aplastic anemia: treatment patterns and outcomes in the real world","volume":"100","author":"Fattizzo","year":"2025","journal-title":"Am J Hematol"},{"issue":"suppl 1","key":"2026090811322933600_bib16","doi-asserted-by":"crossref","first-page":"5805","DOI":"10.1182\/blood-2022-167951","article-title":"Immunosuppressive therapy-response predicting scoring system for severe aplastic anemia [abstract]","volume":"140","author":"Zhao","year":"2022","journal-title":"Blood"},{"issue":"2","key":"2026090811322933600_bib17","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s12185-016-2009-z","article-title":"Biomarkers for predicting clinical response to immunosuppressive therapy in aplastic anemia","volume":"104","author":"Narita","year":"2016","journal-title":"Int J Hematol"},{"issue":"12","key":"2026090811322933600_bib18","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.3324\/haematol.2023.282781","article-title":"Conditional survival and standardized mortality ratios of patients with severe aplastic anemia surviving at least one year after hematopoietic cell transplantation or immunosuppressive therapy","volume":"108","author":"Nakamura","year":"2023","journal-title":"Haematologica"},{"issue":"2","key":"2026090811322933600_bib19","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s40261-018-0725-2","article-title":"Efficacy and safety of eltrombopag for aplastic anemia: a systematic review and meta-analysis","volume":"39","author":"Hong","year":"2019","journal-title":"Clin Drug Investig"},{"issue":"6","key":"2026090811322933600_bib20","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1182\/bloodadvances.2021006716","article-title":"Efficacy of combined immunosuppression with or without eltrombopag in children with newly diagnosed aplastic anemia","volume":"7","author":"Goronkova","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"2026090811322933600_bib21","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2109965","article-title":"Eltrombopag added to immunosuppression in severe aplastic anemia","volume":"386","author":"Peffault de Latour","year":"2022","journal-title":"N Engl J Med"},{"issue":"12","key":"2026090811322933600_bib22","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1182\/bloodadvances.2021004345","article-title":"Approach to the diagnosis of aplastic anemia","volume":"5","author":"DeZern","year":"2021","journal-title":"Blood Adv"},{"issue":"8","key":"2026090811322933600_bib23","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1182\/blood.2022016508","article-title":"Genetic testing in severe aplastic anemia is required for optimal hematopoietic cell transplant outcomes","volume":"140","author":"McReynolds","year":"2022","journal-title":"Blood"},{"issue":"9","key":"2026090811322933600_bib24","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1007\/s00431-023-05093-y","article-title":"Optimizing diagnostic methods and stem cell transplantation outcomes in pediatric bone marrow failure: a 50-year single center experience","volume":"182","author":"Vissers","year":"2023","journal-title":"Eur J Pediatr"},{"issue":"1","key":"2026090811322933600_bib25","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000506387","article-title":"PNH clones for aplastic anemia with immunosuppressive therapy: a systematic review and meta-analysis","volume":"144","author":"Tu","year":"2021","journal-title":"Acta Haematol"},{"issue":"7","key":"2026090811322933600_bib26","doi-asserted-by":"crossref","first-page":"548","DOI":"10.7326\/M14-1885","article-title":"Guidelines International Network: principles for disclosure of interests and management of conflicts in guidelines","volume":"163","author":"Sch\u00fcnemann","year":"2015","journal-title":"Ann Intern Med"},{"key":"2026090811322933600_bib27","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2026090811322933600_bib28","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"7","key":"2026090811322933600_bib29","doi-asserted-by":"crossref","first-page":"525","DOI":"10.7326\/0003-4819-156-7-201204030-00009","article-title":"Guidelines International Network: toward international standards for clinical practice guidelines","volume":"156","author":"Qaseem","year":"2012","journal-title":"Ann Intern Med"},{"key":"2026090811322933600_bib30","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jclinepi.2020.11.018","article-title":"GRADE concept paper 1: validating the \u201cF.A.C.E\u201d instrument using stakeholder perceptions of feasibility, acceptability, cost, and equity in guideline implement","volume":"131","author":"Pottie","year":"2021","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"2026090811322933600_bib31","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1177\/1744987119880234","article-title":"An overview of the qualitative descriptive design within nursing research","volume":"25","author":"Doyle","year":"2020","journal-title":"J Res Nurs"},{"issue":"3","key":"2026090811322933600_bib32","doi-asserted-by":"crossref","first-page":"e053246","DOI":"10.1136\/bmjopen-2021-053246","article-title":"Defining decision thresholds for judgments on health benefits and harms using the grading of recommendations assessment, development and evaluation (GRADE) evidence to decision (EtD) frameworks: a protocol for a randomised methodological study (GRADE-THRESHOLD)","volume":"12","author":"Morgano","year":"2022","journal-title":"BMJ Open"},{"issue":"3","key":"2026090811322933600_bib33","first-page":"e053246","article-title":"Defining decision thresholds for judgments on health benefits and harms using the grading of recommendations assessment, development, and evaluation (GRADE) evidence to decision (EtD) frameworks: a randomized methodological study (GRADE-THRESHOLD)","volume":"12","author":"Morgano","year":"2025","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"2026090811322933600_bib34","doi-asserted-by":"crossref","first-page":"e027445","DOI":"10.1136\/bmjopen-2018-027445","article-title":"Defining certainty of net benefit: a GRADE concept paper","volume":"9","author":"Alper","year":"2019","journal-title":"BMJ Open"},{"key":"2026090811322933600_bib35","doi-asserted-by":"crossref","first-page":"i2089","DOI":"10.1136\/bmj.i2089","article-title":"GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2. Clinical practice guidelines","volume":"353","author":"Alonso-Coello","year":"2016","journal-title":"BMJ"},{"key":"2026090811322933600_bib36","unstructured":"American Society of Hematology\n          . ASH Policy Statement in Support of Patient Access to Safe and Effective Drugs. Accessed 29 July 2025. https:\/\/www.hematology.org\/advocacy\/policy-statements\/2017\/support-patient-access-safe-effective-drugs."},{"key":"2026090811322933600_bib37","unstructured":"American Society of Hematology\n          . Access to Hematology Care in an Age of Innovation. Accessed 29 July 2025. https:\/\/www.hematology.org\/advocacy\/policy-statements\/2019\/access-to-hematology-care-in-an-age-of-innovation."},{"issue":"11","key":"2026090811322933600_bib46","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1038\/s41375-021-01190-9","article-title":"Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia","volume":"35","author":"Fattizzo","year":"2021","journal-title":"Leukemia"},{"issue":"3","key":"2026090811322933600_bib47","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/bjh.19048","article-title":"A longitudinal analysis of paroxysmal nocturnal haemoglobinuria-type cells in patients with bone marrow failure: results of a prospective multi-centre study in Japan","volume":"203","author":"Ishiyama","year":"2023","journal-title":"Br J Haematol"},{"issue":"7","key":"2026090811322933600_bib48","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.3324\/haematol.2009.017889","article-title":"Paroxysmal nocturnal hemoglobinuria clones in severe aplastic anemia patients treated with horse anti-thymocyte globulin plus cyclosporine","volume":"95","author":"Scheinberg","year":"2010","journal-title":"Haematologica"},{"issue":"8","key":"2026090811322933600_bib49","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1182\/bloodadvances.2021006044","article-title":"Minor PNH clones do not distinguish inherited bone marrow failure syndromes from immune-mediated aplastic anemia","volume":"6","author":"Narita","year":"2022","journal-title":"Blood Adv"},{"issue":"17","key":"2026090811322933600_bib50","first-page":"2100","article-title":"Differential diagnosis of bone marrow failure syndromes guided by machine learning","volume":"141","author":"Gutierrez-Rodrigues","year":"2023","journal-title":"Blood"},{"issue":"12","key":"2026090811322933600_bib51","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1038\/s41375-023-02047-z","article-title":"Deciphering treatment patterns in non-severe\/moderate aplastic anemia: an international observational study","volume":"37","author":"Fattizzo","year":"2023","journal-title":"Leukemia"},{"issue":"9","key":"2026090811322933600_bib52","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1038\/s41375-022-01636-8","article-title":"Predictors of clonal evolution and myeloid neoplasia following immunosuppressive therapy in severe aplastic anemia","volume":"36","author":"Groarke","year":"2022","journal-title":"Leukemia"},{"issue":"1","key":"2026090811322933600_bib53","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1200\/JCO.22.00710","article-title":"Clinical and molecular determinants of clonal evolution in aplastic anemia and paroxysmal nocturnal hemoglobinuria","volume":"41","author":"Gurnari","year":"2023","journal-title":"J Clin Oncol"},{"issue":"17","key":"2026090811322933600_bib54","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1182\/blood-2014-05-574889","article-title":"Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome","volume":"124","author":"Kulasekararaj","year":"2014","journal-title":"Blood"},{"issue":"8","key":"2026090811322933600_bib55","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1007\/s10238-023-01067-4","article-title":"Clinical implications of myeloid malignancy-related somatic mutations in aplastic anemia","volume":"23","author":"Liu","year":"2023","journal-title":"Clin Exp Med"},{"key":"2026090811322933600_bib56","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/S0145-2126(15)30067-9","article-title":"Subclinical ancestral events for progression to manifest clonal myelodysplasia are present in aplastic anemia at presentation: comparison of de novo and post AA MDS","volume":"39","author":"Negoro","year":"2015","journal-title":"Leuk Res"},{"issue":"17","key":"2026090811322933600_bib57","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1182\/blood-2017-02-767731","article-title":"Origins of myelodysplastic syndromes after aplastic anemia","volume":"130","author":"Negoro","year":"2017","journal-title":"Blood"},{"issue":"4","key":"2026090811322933600_bib58","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/bjh.14691","article-title":"Telomere length and somatic mutations in correlation with response to immunosuppressive treatment in aplastic anaemia","volume":"178","author":"Park","year":"2017","journal-title":"Br J Haematol"},{"issue":"1","key":"2026090811322933600_bib59","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood.2021012130","article-title":"Long-term outcomes in patients with severe aplastic anemia treated with immunosuppression and eltrombopag: a phase 2 study","volume":"139","author":"Patel","year":"2022","journal-title":"Blood"},{"issue":"22","key":"2026090811322933600_bib60","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1182\/blood.V128.22.727.727","article-title":"Myeloid neoplasm gene somatic mutations in patients with severe aplastic anemia treated with eltrombopag and standard immunosuppression","volume":"128","author":"Townsley","year":"2016","journal-title":"Blood"},{"issue":"21","key":"2026090811322933600_bib61","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1182\/blood.V122.21.2464.2464","article-title":"Spectrum of genetic alterations in acquired aplastic anemia","volume":"122","author":"Yoshizato","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2026090811322933600_bib62","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1414799","article-title":"Somatic mutations and clonal hematopoiesis in aplastic anemia","volume":"373","author":"Yoshizato","year":"2015","journal-title":"N Engl J Med"},{"issue":"19","key":"2026090811322933600_bib63","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1056\/NEJM199105093241901","article-title":"Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group","volume":"324","author":"Frickhofen","year":"1991","journal-title":"N Engl J Med"},{"issue":"11","key":"2026090811322933600_bib64","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1182\/blood.V85.11.3058.bloodjournal85113058","article-title":"Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia","volume":"85","author":"Rosenfeld","year":"1995","journal-title":"Blood"},{"issue":"5","key":"2026090811322933600_bib65","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1056\/NEJMoa1103975","article-title":"Horse versus rabbit antithymocyte globulin in acquired aplastic anemia","volume":"365","author":"Scheinberg","year":"2011","journal-title":"N Engl J Med"},{"issue":"17","key":"2026090811322933600_bib66","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1056\/NEJMra1413485","article-title":"Aplastic anemia","volume":"379","author":"Young","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"2026090811322933600_bib67","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1182\/blood-2011-12-274019","article-title":"How I treat acquired aplastic anemia","volume":"120","author":"Scheinberg","year":"2012","journal-title":"Blood"},{"issue":"5","key":"2026090811322933600_bib68","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00277-010-1140-9","article-title":"Long-term follow-up of clonal evolutions in 802 aplastic anemia patients: a single-center experience","volume":"90","author":"Li","year":"2011","journal-title":"Ann Hematol"},{"issue":"3","key":"2026090811322933600_bib69","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1182\/blood-2016-01-636381","article-title":"Clonal hematopoiesis in acquired aplastic anemia","volume":"128","author":"Ogawa","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2026090811322933600_bib70","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1182\/blood.V97.4.895","article-title":"Telomere length in leukocyte subpopulations of patients with aplastic anemia","volume":"97","author":"Br\u00fcmmendorf","year":"2001","journal-title":"Blood"},{"issue":"suppl_1","key":"2026090811322933600_bib71","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.1182\/blood-2019-130754","article-title":"Telomeric length to characterize and prognosticate bone marrow failure, risk of clonal evolution and multi-system complications in aplastic anemia and other hypocellular cytopenic disorders, independent of telomere gene complex mutations [abstract]","volume":"134","author":"Gandhi","year":"2019","journal-title":"Blood"},{"issue":"3","key":"2026090811322933600_bib72","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/cei\/uxae076","article-title":"Unveiling immunological signatures and predictors of response to immunosuppressive therapy in acquired aplastic anemia","volume":"218","author":"Gupta","year":"2024","journal-title":"Clin Exp Immunol"},{"issue":"21","key":"2026090811322933600_bib73","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1182\/blood.V124.21.4396.4396","article-title":"Long-term outcomes of accelerated telomere shortening in acquired aplastic anemia","volume":"124","author":"Kulagin","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2026090811322933600_bib74","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1046\/j.1365-2141.2001.02669.x","article-title":"Telomere length changes in patients with aplastic anaemia","volume":"112","author":"Lee","year":"2001","journal-title":"Br J Haematol"},{"issue":"12","key":"2026090811322933600_bib75","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.3324\/haematol.2015.132530","article-title":"Paroxysmal nocturnal hemoglobinuria and telomere length predicts response to immunosuppressive therapy in pediatric aplastic anemia","volume":"100","author":"Narita","year":"2015","journal-title":"Haematologica"},{"issue":"22","key":"2026090811322933600_bib76","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood.V128.22.1504.1504","article-title":"Telomere length and somatic mutation in aplastic anemia- correlation with response to treatment","volume":"128","author":"Park","year":"2016","journal-title":"Blood"},{"issue":"21","key":"2026090811322933600_bib77","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1182\/blood.V118.21.4381.4381","article-title":"Increased telomere length is a negative a predicting factor for IST in children with severe aplastic anemia?","volume":"118","author":"Pawelec","year":"2011","journal-title":"Blood"},{"issue":"12","key":"2026090811322933600_bib78","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1001\/jama.2010.1376","article-title":"Association of telomere length of peripheral blood leukocytes with hematopoietic relapse, malignant transformation, and survival in severe aplastic anemia","volume":"304","author":"Scheinberg","year":"2010","journal-title":"JAMA"},{"issue":"9","key":"2026090811322933600_bib79","first-page":"771","article-title":"The relationship of telomere and telomerase activity with outcome of aplastic anemia after immunosuppressive therapy","volume":"34","author":"Song","year":"2013","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"16","key":"2026090811322933600_bib80","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJMoa1613878","article-title":"Eltrombopag added to standard immunosuppression for aplastic anemia","volume":"376","author":"Townsley","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"2026090811322933600_bib81","first-page":"375","article-title":"Telomere length and telomerase mutations in peripheral blood leukocytes of children with chronic aplastic anemia","volume":"16","author":"Wang","year":"2014","journal-title":"Chin J Contemp Pediatr"},{"issue":"2","key":"2026090811322933600_bib82","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/bjh.16153","article-title":"Pre-transplant short telomeres are associated with high mortality risk after unrelated donor haematopoietic cell transplant for severe aplastic anaemia","volume":"188","author":"Wang","year":"2020","journal-title":"Br J Haematol"},{"issue":"24","key":"2026090811322933600_bib83","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1056\/NEJMra0903373","article-title":"Telomere diseases","volume":"361","author":"Calado","year":"2009","journal-title":"N Engl J Med"},{"issue":"5","key":"2026090811322933600_bib84","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1182\/blood-2007-02-075598","article-title":"Very short telomere length by flow fluorescence in situ hybridization identifies patients with dyskeratosis congenita","volume":"110","author":"Alter","year":"2007","journal-title":"Blood"},{"issue":"2","key":"2026090811322933600_bib85","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/BF02983381","article-title":"Outcome of adult severe or very severe aplastic anemia treated with immunosuppressive therapy compared with bone marrow transplantation: multicenter trial","volume":"78","author":"Ahn","year":"2003","journal-title":"Int J Hematol"},{"issue":"1","key":"2026090811322933600_bib86","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0037-1963(00)90031-3","article-title":"Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy-The European Group for Blood and Marrow Transplantation experience","volume":"37","author":"Bacigalupo","year":"2000","journal-title":"Seminars in Hematology"},{"issue":"2","key":"2026090811322933600_bib87","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s12185-016-2037-8","article-title":"Bone marrow transplantation versus immunosuppressive therapy in patients with acquired severe aplastic anemia","volume":"104","author":"Bacigalupo","year":"2016","journal-title":"Int J Hematol"},{"issue":"11","key":"2026090811322933600_bib88","first-page":"1421","article-title":"Treatment of acquired severe aplastic anemia in pediatric patients with immunosuppression and allogeneic stem cell hematopoietic transplant","volume":"135","author":"Barriga","year":"2007","journal-title":"Revista Med de Chile"},{"issue":"3","key":"2026090811322933600_bib89","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s00277-024-05621-2","article-title":"Relapse and transformation to myelodysplastic syndrome and acute myeloid leukemia following immunosuppressive therapy for aplastic anemia is more common as compared to allogeneic stem cell transplantation with a negative impact on survival","volume":"103","author":"Chattopadhyay","year":"2024","journal-title":"Ann Hematol"},{"issue":"4","key":"2026090811322933600_bib90","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/bjh.13297","article-title":"Outcome of aplastic anaemia in children. A study by the Severe Aplastic Anaemia and Paediatric Disease Working Parties of the European Group Blood and Bone Marrow Transplant","volume":"169","author":"Dufour","year":"2015","journal-title":"Br J Haematol"},{"issue":"21","key":"2026090811322933600_bib91","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1182\/blood.V124.21.4382.4382","article-title":"Pediatric aplastic anemia and refractory cytopenia of childhood: a retrospective single institutional analysis to determine outcomes and histomorphological predictors","volume":"124","author":"Forester","year":"2014","journal-title":"Blood"},{"issue":"11","key":"2026090811322933600_bib92","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1038\/sj.bmt.1702699","article-title":"Improved survival in severe acquired aplastic anemia of childhood","volume":"26","author":"Fouladi","year":"2000","journal-title":"Bone Marrow Transpl"},{"issue":"3-4","key":"2026090811322933600_bib93","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00508-013-0484-2","article-title":"Evaluation of treatment responses and colony-forming progenitor cells in 50 patients with aplastic anemia after immunosuppressive therapy or hematopoietic stem cell transplantation: a single-center experience","volume":"126","author":"F\u00fcreder","year":"2014","journal-title":"Wien Klin Wochenschr"},{"issue":"18","key":"2026090811322933600_bib38","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1182\/blood-2014-02-522128","article-title":"Paroxysmal nocturnal hemoglobinuria","volume":"124","author":"Brodsky","year":"2014","journal-title":"Blood"},{"issue":"12","key":"2026090811322933600_bib39","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1182\/blood-2005-04-1717","article-title":"Diagnosis and management of paroxysmal nocturnal hemoglobinuria","volume":"106","author":"Parker","year":"2005","journal-title":"Blood"},{"issue":"7","key":"2026090811322933600_bib40","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s00277-020-04052-z","article-title":"Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the International PNH Registry","volume":"99","author":"Schrezenmeier","year":"2020","journal-title":"Ann Hematol"},{"issue":"26","key":"2026090811322933600_bib41","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1182\/blood.2024025975","article-title":"Pathogenesis of paroxysmal nocturnal hemoglobinuria","volume":"145","author":"Luzzatto","year":"2025","journal-title":"Blood"},{"issue":"suppl 1","key":"2026090811322933600_bib42","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/ijlh.13011","article-title":"Sensitive and accurate identification of PNH clones based on ICCS\/ESCCA PNH consensus guidelines-A summary","volume":"41","author":"Illingworth","year":"2019","journal-title":"Int J Lab Hematol"},{"issue":"1","key":"2026090811322933600_bib43","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ejh.13059","article-title":"Screening and diagnostic clinical algorithm for paroxysmal nocturnal hemoglobinuria: expert consensus","volume":"101","author":"R\u00f6th","year":"2018","journal-title":"Eur J Haematol"},{"issue":"4","key":"2026090811322933600_bib44","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/bjh.12661","article-title":"Prognostic value of paroxysmal nocturnal haemoglobinuria clone presence in aplastic anaemia patients treated with combined immunosuppression: results of two-centre prospective study","volume":"164","author":"Kulagin","year":"2014","journal-title":"Br J Haematol"},{"issue":"4","key":"2026090811322933600_bib45","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1182\/blood-2005-06-2485","article-title":"Minor population of CD55-CD59- blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia","volume":"107","author":"Sugimori","year":"2006","journal-title":"Blood"},{"issue":"2","key":"2026090811322933600_bib94","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3109\/08880010903540542","article-title":"Allogeneic hematopoietic stem cell transplantation is superior to immunosuppressive therapy in Indian children with aplastic anemia\u2014a single-center analysis of 100 patients","volume":"27","author":"George","year":"2010","journal-title":"Pediatr Hematol Oncol"},{"issue":"2","key":"2026090811322933600_bib95","doi-asserted-by":"crossref","first-page":"S221","DOI":"10.1016\/j.bbmt.2014.11.340","article-title":"Allogeneic stem cell transplantation is superior to immunosuppressive therapy in children with aplastic anaemia\u2013a single centre analysis from India","volume":"21","author":"George","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2026090811322933600_bib96","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s12185-016-2037-8","article-title":"Bone marrow transplantation versus immunosuppressive therapy in severe aplastic anemia","volume":"104","author":"Ghavamzadeh","year":"2016","journal-title":"Int J Hematol"},{"issue":"3","key":"2026090811322933600_bib97","first-page":"304","article-title":"Severe acquired aplastic anemia in children: 11-year experience with bone marrow transplantation and immunosuppressive therapy","volume":"11","author":"Halp\u00e9rin","year":"1989","journal-title":"Am J Pediatr Hematol Oncol"},{"issue":"9","key":"2026090811322933600_bib98","first-page":"586.e1","article-title":"Frontline therapy options for adults with newly diagnosed severe aplastic anemia: intensive immunosuppressive therapy plus eltrombopag or matched sibling donor hematopoietic stem cell transplantation?","volume":"28","author":"Huang","year":"2022","journal-title":"Transpl Cell Ther"},{"issue":"7","key":"2026090811322933600_bib99","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1093\/milmed\/167.7.541","article-title":"A retrospective analysis of long-term survival in severe aplastic anemia patients treated with allogeneic bone marrow transplantation or immunosuppressive therapy with antithymocyte globulin and cyclosporin A at a single institution","volume":"167","author":"Ellis","year":"2002","journal-title":"Mil Med"},{"issue":"3","key":"2026090811322933600_bib100","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3346\/jkms.2003.18.3.365","article-title":"The treatment of severe aplastic anemia: outcomes of bone marrow transplantation and immunosuppressive therapy in a single institution of Korea","volume":"18","author":"Kim","year":"2003","journal-title":"J Korean Med Sci"},{"issue":"1","key":"2026090811322933600_bib101","first-page":"321","article-title":"Long-term outcome of acquired aplastic anaemia in children: comparison between immunosuppressive therapy and bone marrow transplantation","volume":"111","author":"Kojima","year":"2000","journal-title":"Br J Haematol"},{"issue":"2","key":"2026090811322933600_bib102","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/00043426-199703000-00004","article-title":"Immunosuppressive therapy: a potential alternative to bone marrow transplantation as initial therapy for acquired severe aplastic anemia in childhood?","volume":"19","author":"Lawlor","year":"1997","journal-title":"J Pediatr Hematol Oncol"},{"issue":"1","key":"2026090811322933600_bib103","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3324\/haematol.10075","article-title":"Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT)","volume":"92","author":"Locasciulli","year":"2007","journal-title":"Haematologica"},{"issue":"3","key":"2026090811322933600_bib104","first-page":"211","article-title":"Treatment with marrow transplantation or immunosuppression of childhood acquired severe aplastic anemia: a report from the EBMT SAA Working Party","volume":"6","author":"Locasciulli","year":"1990","journal-title":"Bone Marrow Transpl"},{"issue":"21","key":"2026090811322933600_bib105","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1182\/blood.V122.21.2108.2108","article-title":"The comparison of clinical outcomes between matched sibling stem cell transplantation and immunosuppressive treatment as a first-line treatment for adult patients with severe aplastic anemia","volume":"122","author":"Shin","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2026090811322933600_bib106","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00277-004-0930-3","article-title":"Quality-adjusted survival analysis shows differences in outcome after immunosuppression or bone marrow transplantation in aplastic anemia","volume":"84","author":"Viollier","year":"2005","journal-title":"Ann Hematol"},{"issue":"12","key":"2026090811322933600_bib107","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.3324\/haematol.2014.109355","article-title":"First-line treatment for severe aplastic anemia in children: bone marrow transplantation from a matched family donor versus immunosuppressive therapy","volume":"99","author":"Yoshida","year":"2014","journal-title":"Haematologica"},{"issue":"suppl 1","key":"2026090811322933600_bib108","doi-asserted-by":"crossref","first-page":"7095","DOI":"10.1182\/blood-2023-179202","article-title":"Comparison of hematopoietic stem cell transplantation and repeated immunosuppressive therapy as second-line treatment for relapsed\/refractory severe aplastic anemia [abstract]","volume":"142","author":"Zhang","year":"2023","journal-title":"Blood"},{"key":"2026090811322933600_bib109","doi-asserted-by":"crossref","first-page":"837335","DOI":"10.3389\/fimmu.2022.837335","article-title":"Comparison of hematopoietic stem cell transplantation outcomes using matched sibling donors, haploidentical donors, and immunosuppressive therapy for patients with acquired aplastic anemia","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"issue":"7","key":"2026090811322933600_bib110","first-page":"409.e1","article-title":"Updated trends in hematopoietic cell transplantation in the United States with an additional focus on adolescent and young adult transplantation activity and outcomes","volume":"28","author":"Phelan","year":"2022","journal-title":"Transpl Cell Ther"},{"issue":"1","key":"2026090811322933600_bib111","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13045-022-01324-1","article-title":"Matched related transplantation versus immunosuppressive therapy plus eltrombopag for first-line treatment of severe aplastic anemia: a multicenter, prospective study","volume":"15","author":"Liu","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"12","key":"2026090811322933600_bib112","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.3324\/haematol.2010.026682","article-title":"Impact of age on outcomes after bone marrow transplantation for acquired aplastic anemia using HLA-matched sibling donors","volume":"95","author":"Gupta","year":"2010","journal-title":"Haematologica"},{"issue":"11","key":"2026090811322933600_bib113","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1182\/blood-2016-08-693481","article-title":"How I treat acquired aplastic anemia","volume":"129","author":"Bacigalupo","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2026090811322933600_bib114","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/bmt.2016.223","article-title":"Immunosuppressive therapy versus alternative donor hematopoietic stem cell transplantation for children with severe aplastic anemia who lack an HLA-matched familial donor","volume":"52","author":"Choi","year":"2017","journal-title":"Bone Marrow Transpl"},{"issue":"4","key":"2026090811322933600_bib115","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/bjh.13614","article-title":"Similar outcome of upfront-unrelated and matched sibling stem cell transplantation in idiopathic paediatric aplastic anaemia. A study on behalf of the UK Paediatric BMT Working Party, Paediatric Diseases Working Party and Severe Aplastic Anaemia Working Party of EBMT","volume":"171","author":"Dufour","year":"2015","journal-title":"Br J Haematol"},{"issue":"10","key":"2026090811322933600_bib116","doi-asserted-by":"crossref","first-page":"e28444","DOI":"10.1002\/pbc.28444","article-title":"A study assessing the feasibility of randomization of pediatric and young adult patients between matched unrelated donor bone marrow transplantation and immune-suppressive therapy for newly diagnosed severe aplastic anemia: a joint pilot trial of the North American Pediatric Aplastic Anemia Consortium and the Pediatric Transplantation and Cellular Therapy Consortium","volume":"67","author":"Pulsipher","year":"2020","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"2026090811322933600_bib117","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41408-024-01021-x","article-title":"Unrelated donor hematopoietic stem cell transplantation compared to immunosuppressive therapy plus eltrombopag as first-line treatment for adults with severe aplastic anemia","volume":"14","author":"Wu","year":"2024","journal-title":"Blood Cancer J"},{"issue":"4","key":"2026090811322933600_bib118","first-page":"442.e1","article-title":"Upfront umbilical cord blood transplantation versus immunosuppressive therapy for pediatric patients with idiopathic severe aplastic anemia","volume":"30","author":"Zhao","year":"2024","journal-title":"Transpl Cell Ther"},{"issue":"9","key":"2026090811322933600_bib119","doi-asserted-by":"crossref","first-page":"e277","DOI":"10.1016\/j.bbmt.2019.05.012","article-title":"The case for upfront HLA-matched unrelated donor hematopoietic stem cell transplantation as a curative option for adult acquired severe aplastic anemia","volume":"25","author":"Marsh","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"7","key":"2026090811322933600_bib120","doi-asserted-by":"crossref","first-page":"e13552","DOI":"10.1111\/petr.13552","article-title":"Allogeneic bone marrow transplants for pediatric severe aplastic anemia: real-world data comparing matched related and unrelated donors in a developing country. Retrospective study on behalf of the Pediatric Hematopoietic Stem Cell Transplant Working Group of the Brazilian Bone Marrow Transplantation Society (SBTMO) and the Brazil-Seattle Consortium (Gedeco)","volume":"23","author":"Darrigo","year":"2019","journal-title":"Pediatr Transpl"},{"issue":"5","key":"2026090811322933600_bib121","doi-asserted-by":"crossref","first-page":"696","DOI":"10.3324\/haematol.2014.115345","article-title":"Current outcome of HLA identical sibling versus unrelated donor transplants in severe aplastic anemia: an EBMT analysis","volume":"100","author":"Bacigalupo","year":"2015","journal-title":"Haematologica"},{"issue":"8","key":"2026090811322933600_bib122","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.bbmt.2019.03.020","article-title":"Comparable outcomes of first-line hematopoietic stem cell transplantation from unrelated and matched sibling donors in adult patients with aplastic anemia: a retrospective single-center study","volume":"25","author":"Zhang","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"3","key":"2026090811322933600_bib123","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/bjh.17232","article-title":"Eltrombopag added to immunosuppression for children with treatment-naive severe aplastic anaemia","volume":"192","author":"Groarke","year":"2021","journal-title":"Br J Haematol"},{"issue":"2","key":"2026090811322933600_bib124","first-page":"103.e1","article-title":"High failure-free survival after unrelated donor peripheral blood stem cell transplantation in pediatric severe aplastic anemia","volume":"28","author":"Yoo","year":"2022","journal-title":"Transpl Cell Ther"},{"issue":"21","key":"2026090811322933600_bib125","doi-asserted-by":"crossref","first-page":"5719","DOI":"10.1182\/bloodadvances.2024013529","article-title":"Consensus recommendations for severe aplastic anemia","volume":"8","author":"Scheinberg","year":"2024","journal-title":"Blood Adv"},{"issue":"4","key":"2026090811322933600_bib126","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMsa1311707","article-title":"HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry","volume":"371","author":"Gragert","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"2026090811322933600_bib127","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/17474086.2023.2191946","article-title":"Hematopoietic cell transplants in resource-poor countries: challenges and opportunities","volume":"16","author":"Jaimovich","year":"2023","journal-title":"Expert Rev Hematol"},{"issue":"3","key":"2026090811322933600_bib128","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1182\/blood-2007-08-099168","article-title":"Prospective multicenter trial comparing repeated immunosuppressive therapy with stem-cell transplantation from an alternative donor as second-line treatment for children with severe and very severe aplastic anemia","volume":"111","author":"Kosaka","year":"2008","journal-title":"Blood"},{"key":"2026090811322933600_bib129","doi-asserted-by":"crossref","first-page":"739561","DOI":"10.3389\/fonc.2021.739561","article-title":"Inefficacy of immunosuppressive therapy for severe aplastic anemia progressing from non-SAA: improved outcome after allogeneic hematopoietic stem cell transplantation","volume":"11","author":"Liu","year":"2021","journal-title":"Front Oncol"},{"key":"2026090811322933600_bib130","doi-asserted-by":"crossref","first-page":"102819","DOI":"10.1016\/j.eclinm.2024.102819","article-title":"Long-term survival after unrelated donor marrow transplantation for aplastic anaemia after optimized conditioning regimen: a retrospective multicentre cohort study","volume":"76","author":"Eapen","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"17","key":"2026090811322933600_bib131","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1182\/blood-2017-09-807859","article-title":"Transplant outcome for patients with acquired aplastic anemia over the age of 40: has the outcome improved?","volume":"131","author":"Giammarco","year":"2018","journal-title":"Blood"},{"issue":"10","key":"2026090811322933600_bib132","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.bbmt.2012.03.015","article-title":"Allogeneic hematopoietic stem cell transplant for adults over 40 years old with acquired aplastic anemia","volume":"18","author":"Kim","year":"2012","journal-title":"Biol Blood Marrow Transpl"},{"issue":"20","key":"2026090811322933600_bib133","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1182\/bloodadvances.2019000722","article-title":"Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia","volume":"3","author":"Bejanyan","year":"2019","journal-title":"Blood Adv"},{"issue":"1","key":"2026090811322933600_bib134","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s41687-018-0032-y","article-title":"Value of transfusion independence in severe aplastic anemia from patients' perspectives - a discrete choice experiment","volume":"2","author":"Pickard","year":"2017","journal-title":"J Patient Rep Outcomes"},{"issue":"20","key":"2026090811322933600_bib135","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1182\/bloodadvances.2019000480","article-title":"Similar outcomes of alemtuzumab-based hematopoietic cell transplantation for SAA patients older or younger than 50 years","volume":"3","author":"Sheth","year":"2019","journal-title":"Blood Adv"},{"issue":"2","key":"2026090811322933600_bib136","doi-asserted-by":"crossref","first-page":"e13179","DOI":"10.1111\/ctr.13179","article-title":"First-line choice for severe aplastic anemia in children: transplantation from a haploidentical donor vs immunosuppressive therapy","volume":"32","author":"Cheng","year":"2018","journal-title":"Clin Transpl"},{"issue":"S1","key":"2026090811322933600_bib137","first-page":"1","article-title":"Outcomes of patients with monosomy 7 evolved from severe aplastic anemia: transplant versus chemotherapy and supportive care","volume":"4","author":"Groarke","year":"2020","journal-title":"HemaSphere"},{"issue":"10","key":"2026090811322933600_bib138","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/s41409-024-02377-1","article-title":"First-line treatment of severe aplastic anemia: immunosuppressive therapy plus eltrombopag versus haploidentical hematopoietic stem cell transplantation, a multicenter prospective study","volume":"59","author":"Liu","year":"2024","journal-title":"Bone Marrow Transpl"},{"issue":"23","key":"2026090811322933600_bib139","doi-asserted-by":"crossref","first-page":"5508","DOI":"10.1182\/blood.V126.23.5508.5508","article-title":"Haploidentical\/mismatched hematopoietic stem cell transplantation for nonresponders to immunosuppressive therapy compared with first-line rabbit antithymocyte immunoglobulin treatment against acquired severe aplastic anemia","volume":"126","author":"Liu","year":"2015","journal-title":"Blood"},{"issue":"8","key":"2026090811322933600_bib140","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1007\/s00277-023-05256-9","article-title":"Comparison of haploidentical\u2013allogeneic hematopoietic stem cell transplantation and intensive immunosuppressive therapy for patients with severe aplastic anemia with an absolute neutrophil count of zero: a retrospective study","volume":"102","author":"Wu","year":"2023","journal-title":"Ann Hematol"},{"issue":"8","key":"2026090811322933600_bib141","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1038\/s41409-018-0410-3","article-title":"Immunosuppressive therapy versus haploidentical transplantation in adults with acquired severe aplastic anemia","volume":"54","author":"Xu","year":"2019","journal-title":"Bone Marrow Transpl"},{"issue":"5","key":"2026090811322933600_bib142","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.bbmt.2019.01.017","article-title":"Comparison of outcomes of frontline immunosuppressive therapy and frontline haploidentical hematopoietic stem cell transplantation for children with severe aplastic anemia who lack an HLA-matched sibling donor","volume":"25","author":"Yang","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"key":"2026090811322933600_bib143","doi-asserted-by":"crossref","first-page":"1146997","DOI":"10.3389\/fimmu.2023.1146997","article-title":"Comparison of hematopoietic stem cell transplantation and immunosuppressive therapy as the first-line treatment option for patients with severe hepatitis\u2212associated aplastic anemia","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"issue":"2","key":"2026090811322933600_bib144","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1097\/MJT.0000000000000366","article-title":"Comparison of haploidentical hematopoietic stem cell transplantation and immunosuppressive therapy for the treatment of acquired severe aplastic anemia in pediatric patients","volume":"24","author":"Zhang","year":"2017","journal-title":"Am J Ther"},{"issue":"15","key":"2026090811322933600_bib145","first-page":"1161","article-title":"Clinical observation of haploidentical hematopoietic stem cell transplantation combined with intensive immunosuppressive therapy for severe aplastic anemia in children","volume":"35","author":"Zhang","year":"2020","journal-title":"Chin J Appl Clin Pediatr"},{"issue":"3","key":"2026090811322933600_bib146","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/bmt.2016.281","article-title":"Haploidentical transplantation for pediatric patients with acquired severe aplastic anemia","volume":"52","author":"Xu","year":"2017","journal-title":"Bone Marrow Transpl"},{"issue":"25","key":"2026090811322933600_bib147","first-page":"3031","article-title":"Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia","volume":"141","author":"DeZern","year":"2023","journal-title":"Blood"},{"issue":"3","key":"2026090811322933600_bib148","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.bbmt.2016.12.628","article-title":"Alternative donor transplantation with high-dose post-transplantation cyclophosphamide for refractory severe aplastic anemia","volume":"23","author":"DeZern","year":"2017","journal-title":"Biol Blood Marrow Transpl"},{"issue":"10","key":"2026090811322933600_bib149","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.3324\/haematol.2014.106096","article-title":"Outcome of aplastic anemia in adolescence: a survey of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"99","author":"Dufour","year":"2014","journal-title":"Haematologica"},{"issue":"5","key":"2026090811322933600_bib150","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.3324\/haematol.2019.222562","article-title":"Long-term outcome of a randomized controlled study in patients with newly diagnosed severe aplastic anemia treated with antithymocyte globulin and cyclosporine, with or without granulocyte colony-stimulating factor: a Severe Aplastic Anemia Working Party Trial from the European Group of Blood and Marrow Transplantation","volume":"105","author":"Tichelli","year":"2020","journal-title":"Haematologica"},{"issue":"4","key":"2026090811322933600_bib151","doi-asserted-by":"crossref","first-page":"664","DOI":"10.3324\/haematol.2013.089268","article-title":"Long-term outcome after immunosuppressive therapy with horse or rabbit antithymocyte globulin and cyclosporine for severe aplastic anemia in children","volume":"99","author":"Jeong","year":"2014","journal-title":"Haematologica"},{"issue":"21","key":"2026090811322933600_bib152","doi-asserted-by":"crossref","first-page":"4192","DOI":"10.1002\/cncr.31658","article-title":"Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia","volume":"124","author":"Assi","year":"2018","journal-title":"Cancer"},{"issue":"5","key":"2026090811322933600_bib153","first-page":"28","article-title":"Effects of Eltrombopag combined with intensive immunosuppression in treatment of patients with aplastic anemia","volume":"67","author":"Fang","year":"2023","journal-title":"Med J Chin People\u2019s Health"},{"issue":"7","key":"2026090811322933600_bib154","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1080\/08880018.2021.1895924","article-title":"Efficacy and safety of immunosuppressive therapy with or without eltrombopag in pediatric patients with acquired aplastic anemia: a Chinese retrospective study","volume":"38","author":"Fang","year":"2021","journal-title":"Pediatr Hematol Oncol"},{"issue":"3","key":"2026090811322933600_bib155","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/bjh.17232","article-title":"Eltrombopag added to immunosuppression for children with treatment-na\u00efve severe aplastic anaemia","volume":"192","author":"Groarke","year":"2021","journal-title":"Br J Haematol"},{"key":"2026090811322933600_bib156","author":"Hu","year":"2023"},{"issue":"7","key":"2026090811322933600_bib157","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1080\/08880018.2021.1900475","article-title":"Efficacy and safety of eltrombopag in the first-line therapy of severe aplastic anemia in children","volume":"38","author":"Jie","year":"2021","journal-title":"Pediatr Hematol Oncol"},{"issue":"11","key":"2026090811322933600_bib158","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1007\/s00277-022-04966-w","article-title":"A real-word experience of eltrombopag plus rabbit antithymocyte immunoglobulin\u2013based IST in Chinese patients with severe aplastic anemia","volume":"101","author":"Jin","year":"2022","journal-title":"Ann Hematol"},{"issue":"8","key":"2026090811322933600_bib159","doi-asserted-by":"crossref","first-page":"e29066","DOI":"10.1002\/pbc.29066","article-title":"Eltrombopag in children with severe aplastic anemia","volume":"68","author":"Lesmana","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"2026090811322933600_bib160","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1111\/bjh.19648","article-title":"Safety and efficacy of immunosuppressive therapy for elderly patients with severe aplastic anaemia","volume":"205","author":"Prabahran","year":"2024","journal-title":"Br J Haematol"},{"issue":"6","key":"2026090811322933600_bib161","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1007\/s12185-023-03670-3","article-title":"Multicenter evaluation of the addition of eltrombopag to immunosuppressive therapy for adults with severe aplastic anemia","volume":"118","author":"Shinn","year":"2023","journal-title":"Int J Hematol"},{"issue":"1","key":"2026090811322933600_bib162","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3324\/haematol.2021.278413","article-title":"Predicting response of severe aplastic anemia to immunosuppression combined with eltrombopag","volume":"107","author":"Zaimoku","year":"2022","journal-title":"Haematologica"},{"key":"2026090811322933600_bib163","first-page":"348","article-title":"The efficacy of immunosuppression combined with eltrombopag in the treatment of severe aplastic anemia in children","volume":"24","author":"Zhang","year":"2022","journal-title":"Chin J Appl Clin Pediatr"},{"key":"2026090811322933600_bib164","doi-asserted-by":"crossref","first-page":"1095143","DOI":"10.3389\/fped.2022.1095143","article-title":"Efficacy of eltrombopag with immunosuppressive therapy for children with acquired aplastic anemia","volume":"10","author":"Zhao","year":"2023","journal-title":"Front Pediatr"},{"issue":"1","key":"2026090811322933600_bib165","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1200931","article-title":"Eltrombopag and improved hematopoiesis in refractory aplastic anemia","volume":"367","author":"Olnes","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"2026090811322933600_bib166","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.jpeds.2008.06.004","article-title":"Long-term outcome of pediatric patients with severe aplastic anemia treated with antithymocyte globulin and cyclosporine","volume":"153","author":"Scheinberg","year":"2008","journal-title":"J Pediatr"},{"issue":"12","key":"2026090811322933600_bib167","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/ajh.24897","article-title":"Clinical outcomes in adult patients with aplastic anemia: a single institution experience","volume":"92","author":"Boddu","year":"2017","journal-title":"Am J Hematol"},{"issue":"9","key":"2026090811322933600_bib168","doi-asserted-by":"crossref","first-page":"e345","DOI":"10.3324\/haematol.2015.123760","article-title":"Repeat course of rabbit antithymocyte globulin as salvage following initial therapy with rabbit antithymocyte globulin in acquired aplastic anemia","volume":"100","author":"Cl\u00e9","year":"2015","journal-title":"Haematologica"},{"issue":"4","key":"2026090811322933600_bib169","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/j.phoj.2022.10.056","article-title":"Response to the second cycle of immunosuppressive therapy (antithymocyte globulin) in children with aplastic anemia","volume":"7","author":"Nongbet","year":"2022","journal-title":"Pediatr Hematol Oncol J"},{"issue":"3","key":"2026090811322933600_bib170","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1111\/bjh.19648","article-title":"Safety and efficacy of immunosuppressive therapy for elderly patients with severe aplastic anaemia","volume":"205","author":"Prabahran","year":"2024","journal-title":"Br J Haematol"},{"key":"2026090811322933600_bib171","doi-asserted-by":"crossref","first-page":"1425076","DOI":"10.3389\/fimmu.2024.1425076","article-title":"Comparison of hematopoietic stem cell transplantation and repeated intensified immunosuppressive therapy as second-line treatment for relapsed\/refractory severe aplastic anemia","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Immunol"},{"issue":"2","key":"2026090811322933600_bib172","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1046\/j.1365-2141.1998.00578.x","article-title":"Repeated treatment with horse antilymphocyte globulin for severe aplastic anaemia","volume":"100","author":"Tichelli","year":"1998","journal-title":"Br J Haematol"},{"issue":"2","key":"2026090811322933600_bib173","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1046\/j.1365-2141.1999.01693.x","article-title":"Rabbit antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy. Gruppo Italiano Trapianto di Midollo Osseo (GITMO)","volume":"107","author":"Di Bona","year":"1999","journal-title":"Br J Haematol"},{"issue":"6","key":"2026090811322933600_bib174","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1365-2141.2006.06098.x","article-title":"Retreatment with rabbit anti-thymocyte globulin and ciclosporin for patients with relapsed or refractory severe aplastic anaemia","volume":"133","author":"Scheinberg","year":"2006","journal-title":"Br J Haematol"},{"issue":"9","key":"2026090811322933600_bib175","doi-asserted-by":"crossref","first-page":"e660","DOI":"10.1016\/S2352-3026(22)00206-X","article-title":"Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial","volume":"9","author":"DeZern","year":"2022","journal-title":"Lancet Haematol"},{"issue":"2","key":"2026090811322933600_bib176","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1365-2141.1993.tb03181.x","article-title":"Relapse of aplastic anaemia after immunosuppressive treatment: a report from the European Bone Marrow Transplantation Group SAA Working Party","volume":"85","author":"Schrezenmeier","year":"1993","journal-title":"Br J Haematol"},{"key":"2026090811322933600_bib177","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1182\/asheducation-2013.1.87","article-title":"Management of the refractory aplastic anemia patient: what are the options?","volume":"2013","author":"Marsh","year":"2013","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"9","key":"2026090811322933600_bib178","first-page":"2305","article-title":"Graft-versus-host disease and relapse\/rejection-free survival after allogeneic transplantation for idiopathic severe aplastic anemia: a comprehensive analysis from the SAAWP of the EBMT","volume":"108","author":"Devillier","year":"2023","journal-title":"Haematologica"},{"issue":"2","key":"2026090811322933600_bib179","doi-asserted-by":"crossref","first-page":"107","DOI":"10.7326\/0003-4819-126-2-199701150-00003","article-title":"Primary treatment of acquired aplastic anemia: outcomes with bone marrow transplantation and immunosuppressive therapy. Seattle Bone Marrow Transplant Team","volume":"126","author":"Doney","year":"1997","journal-title":"Ann Intern Med"},{"issue":"3","key":"2026090811322933600_bib180","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s12288-022-01597-z","article-title":"Profile and predictors of infection following anti-thymocyte globulin or anti-lymphocyte globulin with cyclosporine in aplastic anemia","volume":"39","author":"Lionel","year":"2023","journal-title":"Indian J Hematol Blood Transfus"},{"key":"2026090811322933600_bib181","first-page":"2463","article-title":"Clinical dissection of infectious event following ATG treatment for aplastic anemia and hypoplastic myelodysplastic syndrome reveals urgent need for anti-aspergillus prophylaxis","volume":"130","author":"Jang","year":"2017","journal-title":"Blood"},{"issue":"8","key":"2026090811322933600_bib182","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/MPH.0000000000000647","article-title":"High-dose cyclophosphamide is effective therapy for pediatric severe aplastic anemia","volume":"38","author":"Gamper","year":"2016","journal-title":"J Pediatr Hematol Oncol"},{"key":"2026090811322933600_bib183","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12878-018-0129-9","article-title":"Infections in patients with aplastic anemia in Chiang Mai University","volume":"18","author":"Lertpongpiroon","year":"2018","journal-title":"BMC Hematol"},{"issue":"6","key":"2026090811322933600_bib184","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1093\/cid\/ciq245","article-title":"Decreased infection-related mortality and improved survival in severe aplastic anemia in the past two decades","volume":"52","author":"Valdez","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2026090811322933600_bib185","doi-asserted-by":"crossref","first-page":"e2021039","DOI":"10.4084\/MJHID.2021.039","article-title":"Invasive fungal diseases in children with acute leukemia and severe aplastic anemia","volume":"13","author":"Supatharawanich","year":"2021","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"2","key":"2026090811322933600_bib186","first-page":"128","article-title":"Posaconazole as primary prevention of fungal infection in intensive immunosuppressive therapy for severe aplastic anemia","volume":"39","author":"Chen","year":"2018","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"3","key":"2026090811322933600_bib187","doi-asserted-by":"crossref","first-page":"e13810","DOI":"10.1111\/ctr.13810","article-title":"Comparable survival outcome between transplantation from haploidentical donor and matched related donor or unrelated donor for severe aplastic anemia patients aged 40 years and older: a retrospective multicenter cohort study","volume":"34","author":"Zhang","year":"2020","journal-title":"Clin Transpl"},{"issue":"1","key":"2026090811322933600_bib188","doi-asserted-by":"crossref","first-page":"14575","DOI":"10.1038\/s41598-020-71571-0","article-title":"Efficacy and safety of posaconazole for the prevention of invasive fungal infections in immunocompromised patients: a systematic review with meta-analysis and trial sequential analysis","volume":"10","author":"Wong","year":"2020","journal-title":"Sci Rep"},{"key":"2026090811322933600_bib189","doi-asserted-by":"crossref","first-page":"891336","DOI":"10.3389\/fphar.2022.891336","article-title":"Antifungal drugs and drug-induced liver injury: a real-world study leveraging the FDA adverse event reporting system database","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Pharmacol"},{"issue":"4","key":"2026090811322933600_bib190","doi-asserted-by":"crossref","first-page":"e872","DOI":"10.1097\/HS9.0000000000000872","article-title":"The European guidelines on diagnosis and management of neutropenia in adults and children: a consensus between the European Hematology Association and the EuNet-INNOCHRON COST Action","volume":"7","author":"Fioredda","year":"2023","journal-title":"Hemasphere"},{"issue":"3","key":"2026090811322933600_bib191","doi-asserted-by":"crossref","first-page":"201","DOI":"10.6004\/jadpro.2023.14.3.4","article-title":"Best practices in the management of infectious complications for patients with cancer: management of febrile neutropenia","volume":"14","author":"Molina","year":"2023","journal-title":"J Adv Pract Oncol"},{"issue":"suppl 5","key":"2026090811322933600_bib192","doi-asserted-by":"crossref","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","article-title":"Management of febrile neutropaenia: ESMO clinical practice guidelines","volume":"27","author":"Klastersky","year":"2016","journal-title":"Ann Oncol"},{"issue":"2","key":"2026090811322933600_bib193","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00277-017-3196-2","article-title":"Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)","volume":"97","author":"Mellinghoff","year":"2018","journal-title":"Ann Hematol"},{"issue":"1","key":"2026090811322933600_bib194","first-page":"Cd004386","article-title":"Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy","volume":"1","author":"Gafter-Gvili","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"2026090811322933600_bib195","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/bjh.19236","article-title":"Guidelines for the diagnosis and management of adult aplastic anaemia: a British Society for Haematology guideline","volume":"204","author":"Kulasekararaj","year":"2024","journal-title":"Br J Haematol"},{"issue":"12","key":"2026090811322933600_bib196","first-page":"1155","article-title":"Allogeneic hematopoietic cell transplantation for the treatment of severe aplastic anemia: evidence-based guidelines from the American Society for Transplantation and Cellular Therapy","volume":"30","author":"Iftikhar","year":"2024","journal-title":"Transpl Cell Ther"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/17\/5962\/2542099\/blooda_adv-2025-019051-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/17\/5962\/2542099\/blooda_adv-2025-019051-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:32:55Z","timestamp":1788881575000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/17\/5962\/567383\/American-Society-of-Hematology-2026-guidelines-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":196,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2026,9,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025019051","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9,8]]},"published":{"date-parts":[[2026,8,28]]}}}